Takeda Pharmaceutical Co. (NYSE:TAK – Get Free Report) insider Giles Platford sold 55,617 shares of Takeda Pharmaceutical stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $20.90, for a total value of $1,162,395.30. Following the sale, the insider owned 270,253 shares of the company’s stock, valued at approximately $5,648,287.70. This represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Giles Richard Platford also recently made the following trade(s):
- On Monday, August 10th, Giles Platford sold 31,083 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total value of $531,519.30.
Takeda Pharmaceutical Trading Up 0.8%
NYSE:TAK opened at $21.23 on Friday. The stock’s 50 day moving average price is $19.06 and its 200 day moving average price is $17.64. Takeda Pharmaceutical Co. has a 52 week low of $13.56 and a 52 week high of $21.73. The company has a market capitalization of $68.05 billion, a P/E ratio of 12.03 and a beta of -0.02. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.60 and a current ratio of 1.15.
Wall Street Analysts Forecast Growth
TAK has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Zacks Research upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.
Get Our Latest Stock Report on TAK
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Provenance Wealth Advisors LLC bought a new position in Takeda Pharmaceutical in the 3rd quarter worth $27,000. Nisa Investment Advisors LLC lifted its position in Takeda Pharmaceutical by 28.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,306 shares of the company’s stock worth $42,000 after acquiring an additional 515 shares during the last quarter. TD Waterhouse Canada Inc. bought a new stake in Takeda Pharmaceutical during the third quarter valued at about $59,000. Rockefeller Capital Management L.P. boosted its holdings in Takeda Pharmaceutical by 30.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company’s stock valued at $81,000 after acquiring an additional 1,215 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. boosted its holdings in Takeda Pharmaceutical by 9.9% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 7,881 shares of the company’s stock valued at $143,000 after acquiring an additional 711 shares during the period. 9.17% of the stock is owned by institutional investors.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.
Featured Stories
- Five stocks we like better than Takeda Pharmaceutical
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
